Copyright
©The Author(s) 2024.
World J Hepatol. Oct 27, 2024; 16(10): 1169-1176
Published online Oct 27, 2024. doi: 10.4254/wjh.v16.i10.1169
Published online Oct 27, 2024. doi: 10.4254/wjh.v16.i10.1169
Table 1 Baseline characteristics of patients with metabolic dysfunction-associated steatohepatitis and control, n (%)
| MASH | No MASH | |
| Smoker | 8650 (14.03) | 3629290 (5.24) |
| Male | 26020 (42.21) | 31483000 (45.51) |
| Hyperlipidemia | 43360 (70.35) | 11634530 (16.82) |
| Hypertension | 45520 (73.86) | 13997560 (20.23) |
| T2DM | 34800 (56.46) | 5552250 (8.02) |
| Obesity | 35840 (58.15) | 5123940 (7.40) |
| H. pylori infection | 570 (0.92) | 79420 (0.11) |
| Total | 61630 | 69170990 |
- Citation: Abdel-Razeq R, Bitar L, Bitar ER, Onwuzo C, Abu-Hammour MN, Eren B, Mohamed I, Johnson A, Boustany A, Onwuzo S, Asaad I. Prevalence and risk factors associated with metabolic dysfunction-associated steatohepatitis in patients with Helicobacter pylori infection: A population-based study. World J Hepatol 2024; 16(10): 1169-1176
- URL: https://www.wjgnet.com/1948-5182/full/v16/i10/1169.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i10.1169
